Newsletter # 11
When used in conjunction with pharmacological tools such as scopolamine that induces cognitive deficit (reduction in the recognition index), it becomes a useful model for screening compounds with memory enhancing properties.
Compound testing: Compound testing addresses the reversion of scopolamine-induced cognitive deficit by acute treatment in the rats.
Reversal of scopolamine-induced cognitive deficit in the novel object recognition assay by nicotine. Scopolamine and/or nicotine are given at the beginning of the acquisition trial. Retention trial is performed 30 min after the acquisition trial. Recognition index is the proportion of time spent exploring the novel object.
We look forward to hearing from you.